ORBIT Bleeding Score (AFib)

About ORBIT Bleeding Score (AFib)

ORBIT Bleeding Score

The ORBIT (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) bleeding score was published by O'Brien and colleagues in JAMA Cardiology in 2015 and was derived specifically to address the limitations of earlier AFib bleeding risk scores (HAS-BLED, ATRIA) that were developed in the warfarin era. ORBIT was derived from a contemporary U.S. community-based registry of 9,186 AFib patients, including both warfarin and DOAC users, and validated in a separate cohort of 14,400 patients from the same registry. The score is endorsed by the 2023 ACC/AHA/ACCP/HRS AFib guideline as one of three acceptable bleeding risk scores (alongside HAS-BLED and ATRIA).

What the calculator measures

The ORBIT score estimates 1-year risk of major bleeding (intracranial hemorrhage, major GI bleeding, or other bleeding requiring hospitalization or transfusion) in patients with atrial fibrillation who are receiving oral anticoagulation. Annual major bleeding risks are approximately 1.5% for a score of 0-2, 3-5% for a score of 3-4, and 8-12% for a score of 5-7. The score is most useful for identifying patients at high bleeding risk in whom modifiable risk factors should be aggressively addressed and for whom DOACs (with lower bleeding risk than warfarin) are particularly attractive.

How the formula works

The ORBIT score uses 5 variables, with age and anemia weighted more heavily:

• Age ≥75: 2 points
• Anemia (hemoglobin <13 g/dL in men or <12 g/dL in women): 2 points
• Prior bleeding history: 1 point
• eGFR <60 mL/min/1.73 m²: 1 point
• Concurrent antiplatelet therapy: 1 point

The maximum score is 7. The weighting reflects the relative strength of association with major bleeding: age and anemia are the strongest predictors, each worth 2 points; bleeding history, renal dysfunction, and antiplatelet use are each worth 1 point.

Interpretation

The ORBIT score classifies patients into three risk tiers: low (0-2, ~1.5% annual bleeding), intermediate (3-4, ~3-5% annual), and high (5-7, ~8-12% annual). As with HAS-BLED, a high score is not a contraindication to anticoagulation but rather a signal to address modifiable bleeding risk factors (antiplatelet use, anemia treatment, renal protection, blood pressure control). In patients with elevated CHA₂DS₂-VASc scores, the stroke prevention benefit of anticoagulation usually outweighs the bleeding risk even when ORBIT is high, provided modifiable factors are addressed.

Clinical use

ORBIT is most useful in three scenarios. First, in patients with anemia. ORBIT includes anemia as a 2-point criterion, while HAS-BLED does not directly capture anemia. Anemia is one of the strongest predictors of bleeding on anticoagulation. Second, in patients on DOACs. ORBIT was derived in a contemporary cohort including DOAC users and is therefore better calibrated for DOAC patients than HAS-BLED, which was derived in the warfarin era. Third, in U.S. community practice. ORBIT was derived in a U.S. registry and may better reflect U.S. patient characteristics than the European-derived HAS-BLED.

Limitations

The ORBIT score has several limitations. First, it does not capture all bleeding risk factors, it excludes liver disease, alcohol use, hypertension control, labile INRs, and NSAID use (which HAS-BLED captures). Second, it does not distinguish between major bleeding subtypes (intracranial, GI, other), which have different clinical implications. Third, it was derived in a U.S. registry and may perform differently in other populations. Fourth, the anemia criterion uses a fixed hemoglobin threshold, which may not capture all clinically significant anemia (e.g. a patient with a recent 3 g/dL drop in hemoglobin who is still above the threshold). Fifth, the eGFR threshold of 60 is binary and does not capture the continuous dose-response relationship between kidney function and bleeding risk.

Comparison with HAS-BLED and ATRIA

The three bleeding scores have overlapping but distinct variables:

• HAS-BLED (9 points max): Hypertension, abnormal renal function, abnormal liver function, prior stroke, prior bleeding, labile INR, age ≥65, drugs (antiplatelet/NSAID), alcohol
• ORBIT (7 points max): Age ≥75, anemia, prior bleeding, eGFR <60, antiplatelet
• ATRIA (10 points max): Anemia, severe renal disease, age ≥75, prior hemorrhage, hypertension

The 2023 ACC/AHA/ACCP/HRS guideline lists all three as acceptable. In practice, the choice often depends on local availability and clinician familiarity. ORBIT may be preferred in DOAC patients (better calibration for contemporary therapy) and in patients with anemia; HAS-BLED may be preferred for its emphasis on modifiable risk factors; ATRIA is less commonly used in current practice.

How to use the result

An ORBIT score of 5 indicates approximately 8-12% annual major bleeding risk. This is not a contraindication to anticoagulation; rather, it should prompt aggressive management of modifiable bleeding risk factors. For most patients with elevated CHA₂DS₂-VASc scores, the stroke prevention benefit outweighs the bleeding risk once modifiable factors are addressed. DOACs are preferred over warfarin in these patients, with apixaban having the lowest major bleeding rate among DOACs in the ARISTOTLE trial.